Factors affecting liver fibrosis in human immunodeficiency virus and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Factors affecting liver fibrosis in human immunodeficiency virus and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy

Benhamou Y, Di Martino V, Bochet M, Colombet G, Thibault V, Liou A, et al. Factors affecting liver fibrosis in human immunodeficiency virus and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology. 2001;34(2):283-287.

Publication Type:

Journal Article

Authors:

Benhamou, Y.; Di Martino, V.; Bochet, M.; Colombet, G.; Thibault, V.; Liou, A.; Katlama, C.; Poynard, T.; The Multivirc Group

Source:

Hepatology, Volume 34, Issue 2, p.283-287 (2001)

Keywords:

Adult, Age of Onset, Alcohol Drinking, analysis, Antiviral Agents, Biopsy, CD4 Lymphocyte Count, Cohort Studies, complications, drug effects, drug therapy, Drug Therapy,Combination, epidemiology, Female, Follow-Up Studies, France, hepatitis, Hepatitis C, HIV Infections, HIV RNA, Human, Liver, Liver Cirrhosis, Male, Multivariate Analysis, pathology, Protease Inhibitors, Retrospective Studies, Risk, therapeutic use, therapy, United States, virology

Cited On:

When and in Whom to Initiate HCV Therapy

External Third-party Web Link:

http://www.ncbi.nlm.nih.gov/pubmed/11481613

Export Citation:

RIS Format

Top